Breast Cancer Vaccine Shows Promise in Early Human Trial
The results were published inJAMA Oncologythis month. Existing treatments for HER2-positive breast cancer, includingmonoclonal antibodies and chemotherapy, can be unsafe or ineffective. Some treatments must be given frequently for a long time. According to the American Cancer Society, about 14% of people with breast cancer are HER2-positive. Breast cancer cells with high levels of HER2 tend to grow and spread faster than HER2-negative breast cancers. Over 80% of the participants who received the medium-dose vaccine were still living a decade later....